1. <menuitem id="mw5yx"></menuitem>
      1. <tbody id="mw5yx"></tbody>

        <track id="mw5yx"></track>

              <tbody id="mw5yx"></tbody>

                NEVER ACCEPT THE
                STATUS QUO

                Our core capabilities for target discovery and validation are enabled by a series of Regeneron-invented technologies that accelerate, improve and disrupt the traditional drug discovery and development process. Collectively, these technologies represent some of the most valuable biotechnologies ever created, and aid our efforts to continuously accelerate the average timeline from discovery to drug approval — ultimately allowing us to help more patients around the world, faster. We will continue to raise the bar for R&D excellence and productivity in the biotech industry.

                VELOCISUITE®

                • VelociGene? biotechnology enables rapid, automated and high-scale manipulation of mouse DNA, with almost no limitations on the size and sophistication of modifications.
                • VelociMouse? is a breakthrough technology that enables the immediate generation of genetically altered mice directly from modified embryonic stem cells, thereby avoiding the need to breed multiple generations.
                • VelocImmune? is our unique technology for producing fully human monoclonal antibodies.
                • VelociMab? is a group of technologies that allow us to move with unprecedented speed from identification of a therapeutic antibody into clinical studies.
                • VelociT? is our unique technology for producing fully human therapeutic T-cell receptors (TCR) against tumor and viral antigens.
                • VelociHum? biotechnology is our immunodeficient mouse platform that can be used to accurately test human therapeutics against human immune cells and to study human tumor models.
                • Veloci-Bi?

                VelociGene® enables rapid, automated and high-scale manipulation of mouse DNA, with almost no limitations on the size and sophistication of modifications. This enables unprecedented speed and capacity for the validation of therapeutic targets and the creation of animal models of human disease. We have a long history and deep expertise in mouse genetics — in 2006, VelociGene was selected by the National Institutes of Health (NIH) as part of its Knockout Mouse Project, an unprecedented effort to determine the function of thousands of unknown genes. Under the NIH grant, we took on the challenge of targeting 3,500 of the most difficult genes.

                VelociMouse® is a breakthrough technology that enables the immediate generation of genetically altered mice directly from modified embryonic stem cells, thereby avoiding the need to breed multiple generations. This technology has dramatically shortened the time needed to engineer genetically modified mice, while at the same time reducing costs and improving precision.

                VelocImmune® is our unique technology for producing fully human monoclonal antibodies. VelocImmune creates a multitude of optimized antibody drug candidates efficiently and directly from immunized mice. This approach overcomes the limitations of traditional platforms by rapidly creating fully human antibodies that tightly bind to therapeutic targets and avoid potential immune responses that may occur in patients receiving antibodies that contain nonhuman (typically mouse) components.

                VelociMab® is a group of technologies that allow us to move with unprecedented speed from identification of a therapeutic antibody into clinical studies. VelociMab enables the high-throughput screening of potential therapeutic antibodies and the rapid generation of cell lines for recombinant human antibodies. It allows researchers to go from mouse immunization to production cell line bioreactor harvest within eight months.

                VelociT is our unique technology for producing fully human therapeutic T-cell receptors (TCR) against tumor and viral antigens.

                VelociHum is our immunodeficient mouse platform that can be used to accurately test human therapeutics against human immune cells and to study human tumor models. Through genetic humanizations, VelociHum mice have been optimized to allow for better development of human immune cells in vivo, as well as to allow for engraftment of primary patient-derived tumors that do not take in other commercially available mice.

                Veloci-Bi allows for the generation of full-length bispecific antibodies similar to native antibodies that are amenable to production by standard antibody manufacturing techniques, and likely to have favorable antibody-like pharmaco kinetic properties.

                • VelociGene? biotechnology enables rapid, automated and high-scale manipulation of mouse DNA, with almost no limitations on the size and sophistication of modifications.

                  VelociGene® enables rapid, automated and high-scale manipulation of mouse DNA, with almost no limitations on the size and sophistication of modifications. This enables unprecedented speed and capacity for the validation of therapeutic targets and the creation of animal models of human disease. We have a long history and deep expertise in mouse genetics — in 2006, VelociGene was selected by the National Institutes of Health (NIH) as part of its Knockout Mouse Project, an unprecedented effort to determine the function of thousands of unknown genes. Under the NIH grant, we took on the challenge of targeting 3,500 of the most difficult genes.

                • VelociMouse? is a breakthrough technology that enables the immediate generation of genetically altered mice directly from modified embryonic stem cells, thereby avoiding the need to breed multiple generations.

                  VelociMouse® is a breakthrough technology that enables the immediate generation of genetically altered mice directly from modified embryonic stem cells, thereby avoiding the need to breed multiple generations. This technology has dramatically shortened the time needed to engineer genetically modified mice, while at the same time reducing costs and improving precision.

                • VelocImmune? is our unique technology for producing fully human monoclonal antibodies.

                  VelocImmune® is our unique technology for producing fully human monoclonal antibodies. VelocImmune creates a multitude of optimized antibody drug candidates efficiently and directly from immunized mice. This approach overcomes the limitations of traditional platforms by rapidly creating fully human antibodies that tightly bind to therapeutic targets and avoid potential immune responses that may occur in patients receiving antibodies that contain nonhuman (typically mouse) components.

                • VelociMab? is a group of technologies that allow us to move with unprecedented speed from identification of a therapeutic antibody into clinical studies.

                  VelociMab® is a group of technologies that allow us to move with unprecedented speed from identification of a therapeutic antibody into clinical studies. VelociMab enables the high-throughput screening of potential therapeutic antibodies and the rapid generation of cell lines for recombinant human antibodies. It allows researchers to go from mouse immunization to production cell line bioreactor harvest within eight months.

                • VelociT? is our unique technology for producing fully human therapeutic T-cell receptors (TCR) against tumor and viral antigens.

                  VelociT is our unique technology for producing fully human therapeutic T-cell receptors (TCR) against tumor and viral antigens.

                • VelociHum? biotechnology is our immunodeficient mouse platform that can be used to accurately test human therapeutics against human immune cells and to study human tumor models.

                  VelociHum is our immunodeficient mouse platform that can be used to accurately test human therapeutics against human immune cells and to study human tumor models. Through genetic humanizations, VelociHum mice have been optimized to allow for better development of human immune cells in vivo, as well as to allow for engraftment of primary patient-derived tumors that do not take in other commercially available mice.

                • Veloci-Bi?

                  Veloci-Bi allows for the generation of full-length bispecific antibodies similar to native antibodies that are amenable to production by standard antibody manufacturing techniques, and likely to have favorable antibody-like pharmaco kinetic properties.

                TRAPS

                Our Trap technology was motivated by a dissatisfaction with the specificity and binding affinity of human antibodies that could be developed using the most-advanced antibody technologies at the time. Building on insights into the basic mechanisms of receptor action discovered at Regeneron, our scientists developed a general approach to create high-affinity blockers for many different types of signaling molecules. This novel Regeneron Trap technology creates circulating "decoy receptors" capable of reducing or eliminating the harmful effects of a signaling protein.

                The People Beind the Science: Regeneron Scientist, Xiaobin
                The People Beind the Science: Regeneron Scientist, Xiaobin

                A little boy sits, surrounded by Legos, his nose deep in his favorite book, 100,000 Whys. As he attempts to unravel the mystery behind the sky's color and the firefly's light, a scientist is born.

                "I was 6 when my parents gave me that book. I loved knowing that there was always a reason. The beauty of science, to me, is that we are learning new 'reasons' all the time.”

                Read Xiaobin's story

                CELL PRODUCTION

                Our EESYR®, FASTR® and NICE® technologies and services significantly increase protein production yields in cell-line development for our research and clinical programs, as well as for our partners:

                • EESYR provides site-specific integration into a transcriptional hot spot in the eukaryotic cell genome, resulting in rapid isolation of cells capable of high-level expression of recombinant therapeutic proteins
                • FASTR is a quantitative cell surface display technology that enables the use of flow cytometry to select eukaryotic cells that secrete the highest levels of recombinant therapeutic proteins
                • NICE enables the control of the expression of secreted, recombinant therapeutic proteins in eukaryotic cells
                怡红院在线 视频免费